The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Budesonide (Budenofalk®) has been accepted for restricted use in the treatment of autoimmune hepatitis. The restriction limits use to non-cirrhotic patients who are intolerant of conventional oral corticosteroids (prednisolone) with severe corticosteroid-related side effects (actual or anticipated) such as psychosis, poorly controlled diabetes or osteoporosis.
Insulin degludec (Tresiba®) has been rejected for use in the treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year. The manufacturer failed to make a submission and as a result this treatment cannot be recommended.
Linagliptin (Trajenta®) has been accepted for use in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
Liraglutide (Victoza®) has been accepted for use in the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with basal insulin when this, together with diet and exercise, does not provide adequate glycaemic control.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« Drug Safety Update - April 2015||Drug Safety Update - May 2015 »|